---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-345874"
form_type: "8-K"
ticker: "SPRB"
cik: "0001683553"
company_name: "SPRUCE BIOSCIENCES, INC."
filed_at: "2026-08-12T13:05:17+00:00"
generated_at: "2026-08-12T13:06:11.849361+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Spruce Biosciences Q2 2026: cash $96.3M, TA-ERT BLA on track for Q4, $5.5M investment

## Summary
- Cash and equivalents $96.3M at Jun 30, 2026 vs $48.9M at Dec 31, 2025; runway into H2 2027.
- Q2 2026 net loss $16.2M ($6.68/share); six-month net loss $28.5M ($14.96/share).
- BLA for TA-ERT (MPS IIIB) expected Q4 2026; TrAnsform confirmatory study to initiate Q4 2026.
- Cure Sanfilippo Foundation and National MPS Society invest combined $5.5M to fund TA-ERT Expanded Access Program.
- Appointed Adrian Quartel, M.D. as CMO (Jul 27, 2026) and Jessica Cohen Pfeffer, M.D. as VP Clinical Development (Aug 3, 2026).

## SEC filing metadata
- accession: 0001193125-26-345874
- form_type: 8-K
- ticker: SPRB
- cik: 0001683553
- company_name: SPRUCE BIOSCIENCES, INC.
- filed_at: 2026-08-12T13:05:17+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1683553/000119312526345874/0001193125-26-345874-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1683553/000119312526345874/sprb-20260812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-345874
- JSON: https://secwatch.observer/filing/0001193125-26-345874.json
- Plain text: https://secwatch.observer/filing/0001193125-26-345874.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.